Fibroblast growth factor 19 stimulates water intake

José Ursic-Bedoya 1,2,6, Carine Chavey 1,5, Guillaume Desandré 1, Lucy Meunier 1,2, Anne-Marie Dupuy 2, Iria Gonzalez-Dopeso Reyes 1, Thierry Tordjmann 6, Eric Assénat 1,2, Urszula Hibner 1, Damien Gregoire 1,6.

ABSTRACT

Fibroblast growth factor 19 (FGF19) is a hormone with pleiotropic metabolic functions, leading to ongoing development of analogues for treatment of metabolic disorders. On the other hand, FGF19 is overexpressed in a sub-group of hepatocellular carcinoma (HCC) patients and has oncogenic properties. It is therefore crucial to precisely define FGF19 effects, notably in the context of chronic exposure to elevated concentrations of the hormone. Here, we used hydrodynamic gene transfer to generate a transgenic mouse model with long-term FGF19 hepatic overexpression. We describe a novel effect of FGF19, namely the stimulation of water intake. This phenotype, lasting at least over a 6-month period, depends on signaling in the central nervous system and is independent of FGF21, although it mimics some of its features. We further show that HCC patients with high levels of circulating FGF19 have a reduced natremia, indicating dipsogenic features. The present study provides evidence of a new activity of FGF19, which could be clinically relevant in the context of FGF19 overexpressing cancers and in the course of treatment of metabolic disorders by FGF19 analogues.

Keywords: Liver; FGFR4; Hepatocellular carcinoma; Hydrodynamic gene transfer; Endocrine

1. INTRODUCTION

Fibroblast growth factor 19, FGF19 (and its mouse ortholog, FGF15), functions as a hormone, notably controlling bile acids synthesis and nutrient metabolism [1]. FGF15/19 has been reported to exert multiple effects in the regulation of glucose and lipid metabolism, as well as in energy expenditure and body adiposity, through its actions on liver, muscle, white adipose tissue and brain [2].

Under physiological conditions, FGF19 is expressed in the post-prandial phase by enterocytes of the terminal ileum [3]. The expression by hepatocytes has also been described in cholestasis disorders by FGF19 analogues. FGF19 belongs to the endocrine FGF subfamily, along with FGF21 and FGF23. Endocrine FGF lack the heparin binding domain found in canonical FGFs and act through the binding to a FGF receptor (FGFR1 to 4) in complex with a co-receptor, β-klotho (KLB) for FGF19 and act through the binding to a FGF receptor (FGFR1c/KLB) for FGF21 [7,8]. While many of the FGF19 activities are thought to be mediated by FGF4/KLB signaling, FGF19 and FGF21 also display overlapping metabolic regulations through activation of FGFR1c/KLB signaling [9], notably in the hypothalamus [10,11]. Because of their metabolic effects, FGF19 and FGF21 pathways are considered as promising therapeutic targets for several diseases [12]. In particular, FGF19 has generated a great interest in pharmaceutical research for treatment of chronic liver diseases such as nonalcoholic steatohepatitis [13,14], primary biliary cholangitis [15] and primary sclerosing cholangitis [16].

On top of its metabolic effects, FGF19/FGF4 pathway shows oncogenic functions in several cancers, notably in hepatocellular carcinoma, the most frequent primary liver cancer. The 11q13.3 genomic region containing FGF19 is frequently amplified in HCC tumors (4–15%) [17–19], and overexpression of FGF19 independently of amplification has also been reported [20,21]. Moreover, HCC patients display higher circulating levels of FGF19 than control population [22]. These findings led to the development of potent and selective FGFR4 inhibitors, as well as monoclonal antibodies [23,24], which are currently tested in clinical trials for FGF19-driven hepatocarcinoma, underscoring the therapeutic promise of targeting the FGF19 pathway in HCC [25].

Because of these paradoxical effects on metabolism and oncogenesis, it is crucial to better delineate the complex interplay of FGF19 roles and actions. In this study, we generated a mouse model of FGF19 overexpression by hepatocytes, and identified a new metabolic effect of FGF19.

1 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France. 2 Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit, Saint-Eloi Hospital, University of Montpellier, France. 3 Biochemistry and Hormonology Department, Lapeyronie Hospital, University of Montpellier, Montpellier, France. 4 Université Paris Saclay, Faculté des Sciences d’Orsay, INSERM U.1193, Bât. 443, 91405, Orsay, France.

* Corresponding author. Institut de Génétique Moléculaire de Montpellier, 1919, route de Mende, 34293 Montpellier Cedex, France. E-mail: damien.gregoire@igmm.cnrs.fr (D. Gregoire).

** Co-first authorship.

Abbreviations: FGF19, fibroblast growth factor 19; HCC, hepatocellular carcinoma; HGT, hydrodynamic gene transfer; FGFR, fibroblast growth factor receptor; FGF15, fibroblast growth factor 15; KLB, β-klotho; HPRT, hypoxanthine phospho-riboisomerase; SB100X, Sleeping Beauty transposase 100X; FXR, farnesoid X receptor; BCLC, Barcelona clinic liver cancer; Meld, Model for end stage liver disease

Received December 17, 2021 • Revision received March 18, 2022 • Accepted March 27, 2022 • Available online 31 March 2022

https://doi.org/10.1016/j.molmet.2022.101483
FGF19, namely the stimulation of water intake. We further report that HCC patients with increased circulating FGF19 concentrations show features of disturbance of the hydrosodic balance.

2. METHODS

2.1. Vectors: cloning of FGF19/15
Plasmids constructs pSBbi-RN-FGF19 and pSBbi-BB-FGF15 were generated by cloning the human FGF19, amplified from Huh7 cDNA, and the murine FGF15, amplified from C57Bl/6J mouse ileum cDNA, into pSBbi-RN and pSBbi-BB plasmids (gifts from Eric Kowarz, Addgene plasmid #60519 and #60521, respectively), previously digested by the restriction enzyme SfiI. Primer sets for amplification of the inserts (with SfiI recognition site):

- FGF19-SfiI-for-5'-ATCGGCTCTGAGCCAGGGAAGTGCCATGCGG-3'
- FGF19-SfiI-rev-5'-CGATGGCCTGACAGGCCGGAATCCTGTCATTTCTG-3'
- FGF15-SfiI-for-5'-ATCGGGCTCTGAGCCAGGGAATTCTGTCATTTCTG-3'
- FGF15-SfiI-rev-5'-CGATGGCCTGACAGGCCGGAATCCCTGTCACTTTCTG-3'
- FGF19dCTD sequence, described by Wu. et al. [26] was amplified from the ORF sequence of FGF19 (residues 1 to 177, including the peptide signal) and the SfiI restriction site were added using the primer forward (5'-ATCGGTCCTGAGCCAGGGAATTCTGTCATTTCTG-3') and reverse (5'-CGATGGCCTGACAGGCCGGAATCCCTGTCACTTTCTG-3'). The amplicon was then cloned onto the pSBbi-RN vector (addgene plasmid #60519) linearized using the SfiI restriction enzyme.

2.2. Animal models
All reported animal procedures were carried out in accordance with the rules of the French Institutional Animal Care and Use Committee and European Community Council (2010/63/EU). Animal studies were approved by institutional ethical committee (Comité d’éthique en expérimentation animale Languedoc-Roussillon (#36)) and by the Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation (Apafis #10278-2018082809241782v1, Apafis #32384-2021070917596346 v2).

Hydrodynamic Gene Delivery: Hydrodynamic injections were performed in 6–8 week-old C57Bl/6J female (unless stated otherwise) mice, as described previously [27,28]. Briefly, 0.1 mL/g body weight of a solution of sterile saline containing plasmids of interest were injected into lateral tail vein over 8 s. After incision of abdominal wall and peritoneum, the left lateral lobe of the liver was pulled out of the mouse body. 5000 cells, resuspended in a solution of sterile saline containing plasmids of interest were injected into lateral tail vein over 8 s, together with sleeping beauty transposase SB100X (2.5 μg). Mice were fasted for 4–6 h then killed by anesthetic overdose with isoflurane. Blood was collected by cardiac puncture and plasma purified by centrifugation. Plasma FGF19, FGF19-CIF and FGF21 were measured by ELISA, according to the manufacturers’ instructions: human FGF19 ELISA kit (Biovendor, RD191107200R), mouse FGF21 ELISA kit (Sigma-Aldrich, EZRMFGF21-26K).

2.5. Bile samples and bile acid pool composition
Mice were fasted for 4–6 h then bile was collected by gallbladder puncture following animal euthanasia. Bile acids measurements were performed on mouse bile by high performance liquid chromatography–tandem mass spectrometry as previously described [31].

2.6. RNA isolation, qPCR
RNA was extracted from liver tissue and purified using RNaseasy mini kit (Qiagen) according to manufacturer’s protocol. Reverse transcription of total RNA (1 μg) was done with QuantiTect Reverse Transcription kit (Qiagen), and cDNA quantified using LC Fast start DNA Master SYBR Green I Mix (Roche) with primers detailed below on LightCycler480 apparatus (Roche). Gene expression levels were normalized with hypoxanthine phospho-ribosyltransferase (HPRT). Primer pairs used for qPCR:

- FGF19 5'-CCAGATGGCTACAATGTGTACC-3' and 5'-CAGCATGGGCAG-GAAATG-3'
- Cyp7a1 5'-TCGCAACCTTTCTGGAGCTTA-3' and 5'-ATCTAGTACTGCG-GAGTTT-3'
- Cyp8b1 5'-CTGTTTCTGGGCTCTATTATC-3' and 5'-TCTCTCCATGC-AAGCTTCTGC-3'
- Fgf15 5'-TGTCAGATGAAGATCCACTCTTTCTCTA-3' and 5'-GGATTCG-GAAATACGAGG-3'

2.7. Human studies
A total of 173 patients from the prospective HCC “Liverpool” cohort conducted in the Montpellier University Hospital were included and analyzed retrospectively. All patients provided written consent for research at the time of their blood collection, in line with international regulations and ICH GCP (International Conference on Harmonization- Good Clinical Practice, Biobank Registration Number DC 2014-2328 AC 2014-2335). Montpellier University Hospital Institutional Review Board committee approved this study (N°
All the patients had FGF19 plasma concentration measured at the inclusion using human FGF19 ELISA kit (Biovendor, RD191107200R), according to the manufacturers' instructions. Meld Na score was calculated with the formula described in the princeps article [32].

2.8. Statistical analyses

Data sets were tested with 2-tailed unpaired Student t tests or Mann-Whitney U tests, correlations were analyzed with Pearson’s r test using Prism Software version 8 (GraphPad). Significant P values are shown as: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Comparisons of the mRNA expression levels between groups were assessed using Mann-Whitney U test. Spearman’s rank-order correlation was used to test the association between continuous variables. Univariate survival analysis was performed using Kaplan-Meier curve with log-rank test.

3. RESULTS

3.1. Mouse model of FGF19 expression

We used hydrodynamic gene transfer (HGT) technique [28,33] to generate a mouse model in which FGF19 is overexpressed by a fraction of hepatocytes. The rapid injection of a large volume of solution (10% w/v) in the tail vein leads to *in vivo* transfection of hepatocytes. Combination of plasmids encoding the Sleeping Beauty transposase SB100X and FGF19 was used to establish stable expression of the human hormone (Figure 1A). We routinely detected by epifluorescence microscopy one to two percent of transfected hepatocytes, which persisted up to 6 months after the injection (Figure 1B). The long-term expression of the transgene was confirmed by RT-qPCR analysis (Figure 1C). The level of FGF19 in plasma, detected by ELISA, was around 10 ng/mL (CI95% = [3.5–15.0]) two weeks post-transfection and remained high, despite its gradual decrease, to reach 1 ng/mL.
at 6 months post-injection (CI\textsubscript{95}\% = [0.76–1.11]) (Figure 1D) [34–36]. These concentrations are supra-physiological, as healthy human subjects display circulating concentrations of 50–590 ng/mL [1]; however, they are close to those observed in a subset of HCC patients [22]. Of note, these pathologically relevant concentrations are 100 to 1000-fold lower than to those reported in a model of AAV infection (1 μg/mL [37]). FGFR19-expressing mice showed the previously characterized transcriptional repression of Cyp7a1 and CypB8t, key enzymes of bile acids synthesis from cholesterol (Figure 1E). Serum 7α-hydroxy-4-cholen-3-one (C4) level, a biomarker of bile acid synthesis, was also significantly reduced on FGFR19-expressing mice (Figure 1E, 10.6 ng/mL CI\textsubscript{95}\% = [4.9; 16.2] for controls vs 1.3 ng/mL CI\textsubscript{95}\% = [0.8; 1.8] for FGFR19, p = 0.0027). The composition of the bile acids pool in the FGFR19-expressing animals was indicative of the inhibition of the classical pathway of bile acids synthesis, accompanied by a stimulation of the alternative pathway (Figure 1E, right panel, and Supplementary Fig. 1). In agreement with previous reports [10,36], FGFR19 had a significant effect on metabolic rate, as indicated by a decrease of the body weight despite increase in food intake (Figure 1F). Histological analysis of livers revealed no visible effect of FGFR19 overexpression (Figure 1G). Altogether, these results indicate that the secreted FGFR19 is active, and that the circulating levels are compatible with its physiological functions.

3.2. FGFR19 overexpression increases water intake

While studying metabolic effects in FGFR19 transgenic mice, we serendipitously observed that their cages were very wet compared to those of control mice, suggesting increased urine production. This prompted us to measure the animals’ water intake. We observed that FGFR19 expressing mice drank 6.6–7.8 mL/day (CI\textsubscript{95}\% of the mean) compared to 2.9–3.1 mL/day for control animals hydrodynamically injected with an empty vector (CI\textsubscript{95}\% = [0.32; 0.39] vs CI\textsubscript{95}\% = [0.15; 0.17] mL/day/g after normalization by body weight; p-value <0.0001) (Figure 2A and Supplementary Fig. 2). Strikingly, this phenotype was stable in time for at least 5 months. The increase of water intake was associated with a significant decrease of urine osmolarity (Figure 2B, 1744 mOsm/kg/H\textsubscript{2}O CI\textsubscript{95}\% = [1512; 1976] for controls vs 723 mOsm/kg/H\textsubscript{2}O CI\textsubscript{95}\% = [568; 879] for FGFR19, p < 0.0001). Measuring urine production in individual metabolic cages revealed that FGFR19’\textsuperscript{+} mice have an increased urine output compared to controls (Figure 2C, 490 μL/day CI\textsubscript{95}\% = [204; 775] for controls vs 2871 μL/day CI\textsubscript{95}\% = [1589; 4153] for FGFR19, p = 0.0003) and confirmed the phenotype of decreased urine osmolarity (Figure 2D). Altogether, these results indicate that FGFR19 overexpression mimics a phenotype of diabetes insipidus.

Next, we assessed the effect of FGFR19 overexpression on water drinking in another experimental system, in which FGFR19 is produced by hepatic tumor cells. To model FGFR19-negative and FGFR19-positive hepatic tumors, we implanted intrahepatic allografts of oncogenic cell lines derived from Myc-sgTrp53 or Myc-sgTrp53-FGFR19 tumors. Both cell lines were driven by c-Myc oncogene in conjunction with inactivation of the p53 tumor suppressor, associated for the latter with FGFR19 expression. Whereas Myc-sgTrp53 tumor development had no impact on water intake, mice injected with FGFR19-expressing cells showed progressive rise of water intake from 0.1 to 0.2 mL/day/g body weight as tumors grew (Figure 2E and Supplementary Fig. 2). Mean circulating FGFR19 levels at 3 weeks injection were in mice injected with Myc-sgTrp53-FGFR19 cells were high: 153 ng/mL (CI\textsubscript{95}\% = [81; 225]), approving those obtained with AAV-driven FGFR19 liver overexpression [37]. Thus, FGFR19-driven increase of water intake by FGFR19 was confirmed in a second experimental model. Importantly, this phenotype might be relevant for the subset of HCC patients overexpressing FGFR19. It is unclear why the drinking phenotype has not been previously described in FGFR19 overexpressing mice [37,38]. We note, however, that it would have probably escaped our notice if we were not directly handling the cages.

To determine if the diabetes insipidus phenotype was sex dependent, we next overexpressed FGFR19 by HGT in C57Bl/6J males. Again, the FGFR19 expression increased water intake, leading to a mean water consumption of 0.31 mL/day/g body weight (CI\textsubscript{95}\% = [0.24; 0.37]) during the first month after HGT (Figure 2F). We next investigated whether the overexpression of FGFR15, the FGFR19 mouse ortholog, also gave rise to the water drinking phenotype. Hydrodynamic gene transfer of FGFR15 encoding plasmid led to levels of hepatic expression indistinguishable from those obtained with FGFR19 in the same experimental set up (Figure 2G). Nevertheless, repression of Cyp7a1 transcription was less efficient, and FGFR15 expression did not significantly increase water intake nor reduced urine osmolarity (Figure 2G). FGFR15 shares only 53% of the amino acid sequence with FGFR19 [39]; notably, FGFR15 has an unpaired cysteine residue (Cys-135) that forms an intermolecular disulfide bridge to structure a homodimer. It has been suggested that this particularity leads to a diminished receptor activation and metabolic effects compared to FGFR19 [37]. In summary, hepatic overexpression of FGFR19 results in supra-physiological circulating biologically active FGFR19, which in turn stimulates water intake, a remarkably robust and long-lasting phenotype.

3.3. FGFR19 effect on the central nervous system

To test if the role of FGFR19 in water homeostasis is central or peripheral, we performed an intraperitoneal injection of 2 mL of water to subject mice to an acute increase in water load. Cumulative urine excretion showed that the FGFR19’\textsuperscript{+} mice displayed a similar response to water loading compared to control mice. This is in contrast with the increased urine output observed in FGFR19’\textsuperscript{+} mice when given free access to water (Figure 3A, 206 μL CI\textsubscript{95}\% = [123; 290] for controls vs 433 μL CI\textsubscript{95}\% = [330; 535] for FGFR19, p = 0.0013, and Figure 2C). These data suggest that FGFR19 has no impact on water clearance but rather stimulates voluntary water intake, presumably via the implication of the central nervous system.

The phenotype we report is reminiscent of what has been described for FGFR21, where pharmacologic administration of the hormone also increased water consumption in mice [29,30,40,41]. In a physiological context, FGFR21 has been shown to stimulate water drinking in response to dehydration caused by metabolic stresses such as ketogenic diet or alcohol consumption [30]. FGFR21 impact on water homeostasis is mediated in part by activation of the neurons of the paraventricular nucleus in the hypothalamus, through activation of FGFR1c/[β]-klotho signaling [30]. FGFR1c has also been shown to exert effects on the central nervous system via FGFR1c/[β]-klotho signaling [11,42,43], suggesting that FGFR1c-mediated stimulation of water consumption might rely on the FGFR1c/[β]-klotho activation in the hypothalamus.

To test this hypothesis, we generated FGFR19\textsuperscript{ΔCTD}, a molecule in which the C-terminal region of FGFR19 was removed (deletion of amino acids 178-216) as previously described [26] (Figure 3B). The C-terminal region is necessary for binding to [β]-klotho, in consequence FGFR19\textsuperscript{ΔCTD} loses the ability to activate FGFR1c, but is still able to bind and activate FGFR4 in hepatocytes via heparin binding [26]. Hepatic overexpression of this mutant following hydrodynamic injection gave rise to similar plasma levels compared to wild-type FGFR19 (mean: 12 ng/mL, CI\textsubscript{95}\% = [6.0; 18.0] ng/mL). It resulted in inhibition of hepatic Cyp7a1 expression (Figure 3B), but had no effect on water intake (Figure 3B,
Thus, stimulation of water consumption by FGF19 is \( \beta \)-klotho dependent while activation of hepatic FGFR4 is not sufficient to elicit this phenotype. This is important because bile acids, the synthesis of which is repressed by the FGF19/FGFR4 pathway, have been proposed as regulators of hydric balance. Notably, it has been shown that inactivation of the bile acid nuclear receptor FXR leads to a decrease in urine osmolality [44] through the regulation of aquaporin water channel (aquaporin 2) in the renal collecting ducts. Our results from experiments with truncated FGF19 make it unlikely that bile acids are involved in the stimulation of water intake by FGF19. Because FGF21 has also been described in the phenotype of sugar appetite [29], we submitted control, FGF19 and FGF19\( ^ {\text{DCTD}} \) mice to a two-bottle preference study between water and 3% sucrose. Strikingly, we observed the same phenotype as with FGF21, i.e. FGF19 overexpressing mice showed reduced appetence for 3% sucrose water (Figure 3C, at week1: \( 91\% \text{ CI}_{95\%} = [83.7; 97.8] \) for controls vs 54\% \( \text{CI}_{95\%} = [37; 72] \) for FGF19, \( p = 0.005 \)). Again, this effect was lost with the expression of the FGF19 mutant FGF19\( ^ {\text{DCTD}} \), unable to bind \( \beta \)-klotho and therefore to activate FGFR1c (Figure 3C). An alternative mechanism for FGF19 phenocopying the FGF21 effect would be that the former increases the latter’s secretion. This is however not the case...
case, as measurements of FGF21 plasma levels indicated that FGF19 expression had no effect on the FGF21 levels (Figure 3D). Overall, we conclude that FGF19 effect on water homeostasis is central and independent of FGF21. It likely occurs through activation of FGFR1c/β-klotho in the hypothalamus.

3.4. HCC patients with high circulating FGF19 have reduced natremia

To explore if the effects of FGF19 on water homeostasis have a clinical relevance, we considered pathological conditions associated with supra-physiological concentrations of FGF19. A subset of patients with hepatocellular carcinoma (HCC) have increased FGF19 serum levels [22], and around 10% of tumors are characterized by the amplification of the FGF19 genomic locus [17,19]. In healthy subjects, FGF19 plasma levels range from 50 to 590 pg/mL [45]. To explore a potential effect on water homeostasis in patients with increased circulating levels of FGF19, we assayed FGF19 concentration in plasma from 173 HCC patients from the “Liverpool Cohort”, held in the Montpellier University Hospital. Most patients were male (89%), had underlying cirrhosis (81%) and multifocal or advanced HCC stage (BCLC B, C or D stage, 73%). We defined three groups based on the result of the FGF19 ELISA assay (Figure 4A): “high FGF19” for the upper quartile ([FGF19] > 603 pg/mL, 43 patients), “intermediate FGF19” for the middle quartiles ([FGF19] between 218 pg/mL and 603 pg/mL, 87 patients) and “low FGF19” for the lower quartile ([FGF19] < 218 pg/mL, 43 patients). “High FGF19” group corresponded to supra-physiological concentrations based on the literature [1,45]. Interestingly, natremia of the “high FGF19” group was significantly lower than of the two other groups (Figure 4B, 140.1 mmol/L CI95% = [139.4; 140.8] for “low FGF19” vs 139.2 mmol/L CI95% = [138.5; 139.9] for “intermediate FGF19” vs 137.1 mmol/L CI95% = [136.2; 138] for “high FGF19”, p < 0.0001). Values of natremia below 140 mmol/L are a major prognostic factor in patients with cirrhosis [32] and natremia is needed to establish the MELD-Na score, currently used to prioritize patients on the liver transplantation waiting list in the United States. It is therefore of particular interest that MELD Na score is significantly lower...
higher in FGF19 high group compared to FGF19 low and intermediate groups. Our results are suggestive of an imbalance in the regulation of the sodium and water homeostasis, potentially via an increased water consumption in a context of effective hypovolemia in this cohort of predominantly cirrhotic patients. Of interest, this effect remains significant when subjects under diuretic treatment or with clinical ascites are excluded from the analysis (data not shown). Moreover, the natremia difference did not seem related to an impaired renal function in “FGF19 high” group (Figure 4C). Thus, our data from HCC patients with increased circulating FGF19 concentrations are consistent with an effect on water sodium balance in patients. Further work is required to establish if a reduction in natremia might have a prognostic value for FGF19-driven hepatocellular carcinoma. Finally, since FGF19 analogs are currently tested in several clinical trials, we suggest that it would be of interest to analyze the newly discovered FGF19 activity, specifically natremia and water intake, in response to these compounds.

4. CONCLUSIONS

Our study describes a novel biological function of FGF19, namely the increase in water intake and urine output caused by high levels of circulating FGF19. This phenotype involves a central regulation, likely through activation of FGFR1c/β-klotho in the hypothalamus, which indicates overlapping functions with FGF21. Importantly, FGF19 is overexpressed in a subset of HCCs and we show that patients with high circulating levels of FGF19 display a reduced natremia, suggestive of a hydrosodic balance disturbance. Since HCC arises mostly in patients with cirrhosis, a hormone inducing hyponatremia in this context has high clinical relevance, as it could trigger hepatic encephalopathy. Furthermore, it would be of interest to determine if the phenotype described in this report is also observed in patients with other tumor types (esophagus, breast, ...) in which the FGF19 gene locus amplification has been described.

Figure 4: Increased FGF19 in hepatocellular carcinoma patients is associated with disturbances of the hydrosodic balance. A. Serum FGF19 distribution in a cohort of 173 patients with advanced HCC (FGF19 measured by ELISA). Median value and values at transitions between low, intermediate and high groups are indicated. B. Natremia (left panel) and MELD-Na score (right panel) in patients of the cohort according to the plasma FGF19 concentration. C. Creatinin clearance in patients of the cohort according to the plasma FGF19 concentration. Mann Whitney test significance is indicated. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. n.s: not significant.
**AUTHOR CONTRIBUTIONS**

JUB: Conceptualization, Methodology, Investigation, Writing-original draft, Writing-review & editing; CC: Conceptualization, Investigation, Writing-review & editing; LM: Investigation; GD: Investigation; IG: Investigation; AD: Resources, Investigation; TT: Resources; EA: Supervision, Funding acquisition, Writing-review & editing; UH: Supervision, Funding acquisition, Writing-original draft, Writing-review & editing; DG: Conceptualization, Investigation, Visualization, Supervision, Funding acquisition, Writing-original draft, Writing-review & editing.

**ACKNOWLEDGMENTS**

We acknowledge Montpellier Biocampus facilities: the imaging facility (MRI), and the “Réseau d’Histologie Expérimentale de Montpellier” - RHEM facility, supported by SRIC Montpellier Cancer (Grant InCa_Inserm_DGOS_12553), the European regional development foundation and the Occitanie region (FEDER-FSE 2014-2020 Langue-doc Roussillon), for the histological analyses. We are grateful to zootecnicos of IGMM animal housing facility, Cédric Orféo, Eve Lasserre, Zoé Lebrere, for their work. We thank Emmanuel Vignal for the osmometer and Anne-Dominique Lajoix for allowing access to metabolic cages. We thank members of our lab for helpful discussions and comments. We acknowledge Montpellier University Hospital research staff and patients included in the Liverpool cohort. This work was funded by EVA-Plan cancer INSERM THE, the Association Française pour l’Etude du Foie (AFEF), and supported by SRIC Montpellier Cancer Grant InCa_Inserm_DGOS_12553. The funders had no role in study design, data collection and analysis or publication process.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**APPENDIX A. SUPPLEMENTARY DATA**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2022.101483.

**REFERENCES**

[1] Angelin, B., Larsson, T.E., Rudling, M., 2012. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metabolism 16(6): 693–705. https://doi.org/10.1016/j.cmet.2012.11.001.

[2] Gadaleta, R.M., Moschetta, A., 2019. Metabolic Messengers: fibroblast growth factor 15/19. Nature Metabolism 1(6):588–594. https://doi.org/10.1038/s42255-019-0074-3.

[3] Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., et al., 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metabolism 2(4):217–225. https://doi.org/10.1016/j.cmet.2005.09.001.

[4] Schaap, F.G., van der Gaag, N.A., Gouma, D.J., Jansen, P.L.M., 2009. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49(4):1228–1235. https://doi.org/10.1002/hep.22771.

[5] Wursch, E., Milkiewicz, M., Wasik, U., Trottier, J., Kampańska-Podhorodecka, A., Elias, E., et al., 2015. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Scientific Reports 5(March):1–13. https://doi.org/10.1038/srep13462.

[6] Hasegawa, Y., Kawai, M., Bebsho, K., Yasuda, K., Ueno, T., Satomura, Y., et al., 2019. CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia. Hepatology Research 49(3):314–323. https://doi.org/10.10111/13245.

[7] Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., et al., 2008. Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Molecular Endocrinology 22(4):1006–1014. https://doi.org/10.1210/me.2007-0212.

[8] Wu, X., Ge, H., Lemon, B., Vandenheuvel, S., Weissmann, J., Hecht, R., et al., 2010. FGF19-induced hepatocyte proliferation is mediated through FGF4R activation. Journal of Biological Chemistry 285(8):5165–5170. https://doi.org/10.1074/jbc.M110.087393.

[9] Wu, A.L., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D.M., et al., 2011. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGF4R-dependent and independent pathways. PLoS One 6(3). https://doi.org/10.1371/journal.pone.0017886.

[10] Lan, T., Morgan, D.A., Rahmouni, K., Sonoda, J., Fu, X., Burgess, S.C., et al., 2017. FGF19, FGF21, and an FGF1/β-klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metabolism 26(5): 709–716.e3. https://doi.org/10.1016/j.cmet.2017.09.005.

[11] Perry, R.J., Lee, S., Lu, L., Zhang, D., Schlessinger, J., Shulman, G.I., 2015. FGF19 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature Communications 6:1–10. https://doi.org/10.1038/ncomms10860.

[12] Degirolamo, C., Sabbà, C., Moschetta, A., 2016. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nature Reviews Drug Discovery 15(1):51–69. https://doi.org/10.1038/nrd.2015.9.

[13] Harrison, S.A., Rinalle, M.E., Abdelmalek, M.F., Trottier, J.F., Paredes, A.H., Arnold, H.L., et al., 2018. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 391(10126):1174–1185. https://doi.org/10.1016/S0140-6736(18)30474-4.

[14] Harrison, S.A., Rossi, S.J., Paredes, A.H., Trottier, J.F., Bashir, M.R., Guy, C.D., et al., 2020. NGM282 improves liver fibrosis and histology in 12 Weeks in patients with nonalcoholic steatohepatitis. Hepatology 71(4):1198–1212. https://doi.org/10.1002/hep.30590.

[15] Mayo, M.J., Wigg, A.J., Leggett, B.A., Arnold, H., Thompson, A.J., Weltman, M., et al., 2018. NGM 282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatology Communications 2(9):1037–1050. https://doi.org/10.1002/hepc.12009.

[16] Hirschfield, G.M., Chazouillères, O., Drenth, J.P., Thorburn, D., Harrison, S.A., Landis, C.S., et al., 2019. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. Journal of Hepatology 70(3):483–493. https://doi.org/10.1016/j.jhep.2018.10.035.

[17] Sawey, E.T., Chantron, M., Cai, C., Wu, G., Zhang, J., Zender, L., et al., 2011. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenic screening. Cancer Cell 19(3):347–358. https://doi.org/10.1016/j.ccr.2011.01.040.

[18] Wang, K., Lim, H.Y., Shi, S., Lee, J., Deng, S., Xie, T., et al., 2013. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58(2):706–717. https://doi.org/10.1002/hep.26402.

[19] Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., et al., 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics 47(5):505–511. https://doi.org/10.1038/ng.3252.

[20] Caruso, S., Calalayad, A.L., Pieti, J., La Bella, T., Rebik, S., Imbeaud, S., et al., 2019. Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response. Gastroenterology 157(3):760–776. https://doi.org/10.1053/j.gastro.2019.05.001.
